Clinical trials: Neck Cancer
Esophageal Squamous Cell Carcinoma
Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas
The purpose of this study is to explore the safety and feasibility of anti-programmed cell death ligand 1(PD-L1) immunotherapy, Adebrelimab, combined with cyclin-dependent kinase 4/6 blockade, Dalpiciclib, as a new neoadjuvant…
- Trial name
- NCT06225921
- Testing
- Adebrelimab, Dalpiciclib 100mg, Dalpiciclib 150mg
- Where
- China
- Volunteers
- 6 people
- Sponsor
- West China Hospital
Squamous Cell Carcinoma of the Head and Neck
Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck
Primary To investigate in patients with relapsed or metastatic squamous cell carcinoma of the head and neck whether progression free survival (PFS) in the arm with cetuximab, paclitaxel and carboplatin based chemotherapy is not…
- Trial name
- CETMET (NCT01830556)
- Testing
- Cetuximab
- Where
- 5 sites in Denmark, Sweden
- Volunteers
- 120 people
- Sponsor
- Karolinska University Hospital
Oropharynx Squamous Cell Carcinoma
Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
The purpose of this study is to find out if the addition of nivolumab can improve 2 year progression free survival (PFS) as compared to standard of care of fractionated radiation therapy (RT) and carboplatin/paclitaxel in…
- Trial name
- NCT03829722
- Testing
- Nivolumab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Michigan Rogel Cancer Center
Esophageal Cancer
Design of the EFECTS Trial
It is well known that there is a considerable postoperative weight loss in patients undergoing esophageal resection for cancer. We believe that this weigh loss can be limited by administering postoperative enteral feeding…
- Trial name
- EFECTS (NCT02017366)
- Testing
- Enteral feeding
- Where
- Belgium
- Sponsor
- University Hospital, Gasthuisberg
Esophageal Cancer
Effect of Concurrent Chemoradiation Therapy on Respiratory Muscle Performance, Lung Function and Functional Capacity in Patients With Local Esophagus Cancer
The purpose of this study is to investigate the effect of concurrent chemoradiation therapy on respiratory muscle performance, lung function and functional capacity in patients with local esophagus cancer.
- Trial name
- NCT03120572
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Mackay Memorial Hospital
Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy
Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the outcomes and identify predictors of neoadjuvant anti-PD-1 plus chemotherapy in locally advanced resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT05740995
- Testing
- neoadjuvant anti-PD-1 plus chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Solid Tumors
A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
This is a phase I, open-label, multicentre study of MEDI4736 administered intravenously with a standard 3+3 dose-escalation phase to evaluate safety, tolerability, and pharmacokinetics in patients with advanced solid tumor…
- Trial name
- NCT01938612
- Testing
- MEDI4736, tremelimumab
- Where
- 21 sites in Japan, South Korea and 1 more
- Volunteers
- 269 people
- Sponsor
- AstraZeneca
Anal Cancer, Colorectal Cancer
Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients
Primary Objectives: To determine the feasibility of a study that would describe changes of certain circulating inflammatory cytokines (interleukin-1, 6, 8, 10, 12, and tumor necrosis factor-alpha [TNF] and symptoms related to…
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00502502
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 205 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer Screening
Community Co-produced Action for Improved Access to Cervical Cancer Screening in Cameroon
Background - The burden of cervical cancer is unequally distributed globally, with over 90% of deaths occurring in low- and middle-income countries (LMICs), mainly due to insufficient uptake of preventive measures such as…
- Trial name
- Act4CC (NCT06640075)
- Testing
- Community co-produced action, Standard screening strategy
- Where
- Cameroon
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Prof. Patrick Petignat
Esophageal Neoplasms, Esophagectomy
Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)
Esophagectomy is the cornerstone of the curative treatment of esophageal carcinoma. Despite this treatment, patients can suffer from locoregional or distant metastatic disease and only a very selected group of patients can be…
- Conditions
- Esophageal Neoplasms, Esophagectomy, Brain Metastases
- Trial name
- METABREC (NCT04654975)
- Testing
- Esophagectomy for esophageal cancer
- Where
- 8 sites in United States, Belgium and 4 more
- Volunteers
- 10,000 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Head and Neck Cancer, Oral Cancer
Rehabilitation Outcomes in Head and Neck Survivors
Head and neck cancer is prevalent in Taiwan, and oral cancer is the most common location. Patients with advanced stage of the disease need extensive tumor excision with neck dissection.
- Trial name
- HNC (NCT03206242)
- Testing
- Physiotherapy
- Where
- Taiwan
- Volunteers
- 65 people
- Sponsor
- Chang Gung Memorial Hospital
Recurrent Head and Neck Squamous Cell Carcinoma
Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer
This phase II trial studies how well intensity-modulated radiotherapy and nivolumab work together in treating patients with head and neck squamous cell cancer that has come back.
- Trial name
- NCT03521570
- Testing
- IMRT, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- Emory University
Head and Neck Cancer, NSCLC
A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer
The study is being performed to assess the MTD, pharmacokinetics (PK), safety, tolerability and preliminary antitumor activity of DBPR112 in patients with head and neck cancer and EGFR mutated lung cancer.
- Trial name
- NCT03246854
- Testing
- DBPR112
- Where
- 2 sites in Taiwan
- Volunteers
- 6 people
- Sponsor
- National Health Research Institutes, Taiwan
Head Cancer Neck
Evaluation of Oncoxin-Viusid® in Head and Neck Cancer
Nutritional supplements containing antioxidants seem to decrease toxicity associated with Radiotherapy (RT) and Chemotherapy (CT) in patients with malignant head and neck tumors.
- Trial name
- NCT03541772
- Testing
- Oncoxin-Viusid®
- Where
- Cuba
- Volunteers
- 60 people
- Sponsor
- Catalysis SL
Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer.
- Conditions
- Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma
- Trial name
- NCT04333537
- Testing
- Chest Radiography, Computed Tomography, Fludeoxyglucose F-18
- Where
- 107 sites in United States, Canada
- Volunteers
- 686 people
- Sponsor
- NRG Oncology
Oral Mucositis
Comparative Efficacy of Rebamipide Gargle And Benzydamine HCL Gargle in Prevention and Management of Chemo- and Radio-therapy-induced Oral Mucositis
evaluate preventive and therapeutic effects of Rebamipide gargle on reducing incidence of oral mucositis in comparison with benzydamine HCL mouthwash.
- Trial name
- NCT04685395
- Testing
- Ribamipide gargle \benzdymine HCL gargel
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
Head and Neck Cancer, Oral Mucositis
The Effect of Hydrogen Water in Oral Mucositis in Head and Neck Cancer Patients After Therapy
Inpatients or outpatients diagnosed with head and neck cancer who met the inclusion and exclusion criteria were referred to the co-investigator(Dr. Chih-Jen Huang and Dr.
- Conditions
- Head and Neck Cancer, Oral Mucositis, Pain, Quality of Life
- Trial name
- NCT05913895
- Testing
- hydrogen water
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck
This phase I/II trial is studying the side effects of erlotinib and to see how well it works in treating patients with metastatic or unresectable non-small cell lung cancer, ovarian cancer, or squamous cell carcinoma (cancer) of…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT00063895
- Testing
- erlotinib hydrochloride, pharmacological study, pharmacogenomic studies
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
Decreasing Postoperative Complications by Goal-Directed Fluid Therapy During Esophageal Resection
Surgery for cancer of the esophagus is associated with a high risk of postoperative complications. It has been shown that the risk of postoperative complications can be decreased by optimising the amount and type of infusion…
- Trial name
- NCT01416077
- Testing
- fluid optimisation
- Where
- Sweden
- Volunteers
- 64 people
- Sponsor
- University Hospital, Linkoeping
Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
Background: Cancers of the female reproductive organs often come back after treatment. A drug called sacituzumab govitecan (SG) has been approved for use in other types of cancers.
- Conditions
- Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma, Recurrent Epithelial Cervical Carcinoma
- Trial name
- NCT06865677
- Testing
- Sacituzumab Govitecan, EKG, Brain MRI
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.